Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03092674
Title Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

acute myeloid leukemia

myelodysplastic syndrome


Cytarabine + Decitabine

Azacitidine + Midostaurin


Azacitidine + Nivolumab


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.